Published in World J Urol on June 17, 2014
En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol (2015) 0.85
The role of lasers in modern urology. Cent European J Urol (2015) 0.77
Laser Ablation for Cancer: Past, Present and Future. J Funct Biomater (2017) 0.75
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol (2013) 6.54
The present and future burden of urinary bladder cancer in the world. World J Urol (2009) 4.56
Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg (2006) 2.52
Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective? BJU Int (2013) 2.03
Economic aspects of bladder cancer: what are the benefits and costs? World J Urol (2009) 1.98
Transurethral partial cystectomy with continuous wave laser for bladder carcinoma. J Urol (2009) 1.39
EAU guidelines on laser technologies. Eur Urol (2012) 1.27
Current evidence for transurethral laser therapy of non-muscle invasive bladder cancer. World J Urol (2011) 1.03
Soft-tissue applications of the holmium:YAG laser in urology. J Endourol (1995) 1.02
Comparing the safety and efficiency of conventional monopolar, plasmakinetic, and holmium laser transurethral resection of primary non-muscle invasive bladder cancer. J Endourol (2010) 0.97
Transuretral resection of the bladder (TURB): analysis of complications using a modified Clavien system in an Italian real life cohort. Eur J Surg Oncol (2013) 0.89
[Destruction of bladder neoplasms by means of transurethral neodym-YAG-laser coagulation]. Helv Chir Acta (1978) 0.86
Holmium:YAG laser treatment of recurrent superficial bladder carcinoma: initial clinical experience. J Endourol (2001) 0.86
Tm:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer: early experience. World J Urol (2011) 0.85
Transurethral en bloc resection of bladder tumors. J Urol (2001) 0.85
Holmium:YAG laser vaporization of recurrent papillary tumours of the bladder under local anaesthesia. BJU Int (2004) 0.84
Safety and efficacy of holmium laser resection for primary nonmuscle-invasive bladder cancer versus transurethral electroresection: single-center experience. Urology (2008) 0.84
History of lasers. World J Urol (2007) 0.83
Use of ureteroscopy and holmium:YAG laser in patients with bleeding diatheses. Urology (1998) 0.83
Comparison of the safety and efficacy of conventional monopolar and 2-micron laser transurethral resection in the management of multiple nonmuscle-invasive bladder cancer. J Int Med Res (2013) 0.82
Thulium laser resection via a flexible cystoscope for recurrent non-muscle-invasive bladder cancer: initial clinical experience. BJU Int (2008) 0.81
Clinical observation on 2 micron laser for non-muscle-invasive bladder tumor treatment: single-center experience. World J Urol (2010) 0.81
Holmium laser resection of bladder tumors (HoLRBT). Tech Urol (1998) 0.81
Current evidence for transurethral en bloc resection of non-muscle-invasive bladder cancer. Minim Invasive Ther Allied Technol (2014) 0.81
Safety and efficacy of 120W high performance system greenlight laser vaporization for non-muscle-invasive bladder cancer. J Xray Sci Technol (2013) 0.80
Holmium YAG laser treatment of superficial bladder carcinoma. Mymensingh Med J (2005) 0.79
Adjuvant laser treatment of bladder cancer: 8 years' experience with the Nd-YAG laser 1064 nm. Br J Urol (1989) 0.79
Holmium laser treatment for low grade, low stage, noninvasive bladder cancer with local anesthesia and early instillation of mitomycin C. J Urol (2007) 0.79
Flexible cystoscopy and Holmium:Yttrium aluminum garnet laser ablation for recurrent nonmuscle invasive bladder carcinoma under local anesthesia. J Endourol (2013) 0.76
Use of the holmium:YAG (Ho:YAG) laser for treatment of superficial bladder carcinoma. Lasers Surg Med (1994) 0.76
Older patients suffer from adverse histopathological features after radical cystectomy. Int J Urol (2011) 0.76
[Urothelial carcinoma of the bladder: evaluation by combined endoscopy and urine cytology: is incontrovertible assessment possible?]. Urologe A (2011) 0.75
ND: YAG nomogram dosimetry scale for the bladder. J Urol (1988) 0.75
Transurethral partial cystectomy with 2 μm thulium continuous wave laser in the treatment of bladder pheochromocytoma. J Endourol (2011) 0.75
EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol (2010) 8.21
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol (2011) 5.59
Renal cell carcinoma guideline. Eur Urol (2007) 3.42
The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol (2009) 2.92
Impact of preoperative ureteral stenting on stone-free rates of ureteroscopy for nephroureterolithiasis: a matched-paired analysis of 286 patients. Urology (2012) 2.70
Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center. Urology (2012) 2.61
120-W 2-µm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up. BJU Int (2011) 2.17
Laparoendoscopic single-site partial nephrectomy: a multi-institutional outcome analysis. Eur Urol (2013) 2.09
Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World J Urol (2012) 1.72
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72
MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol (2006) 1.50
RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up. World J Urol (2007) 1.48
Analysis of oncological outcomes and renal function after laparoendoscopic single-site (LESS) partial nephrectomy: a multi-institutional outcome analysis. BJU Int (2013) 1.42
No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol (2013) 1.40
EAU guidelines on laser technologies. Eur Urol (2012) 1.27
Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? Eur Urol (2010) 1.26
Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol (2011) 1.21
Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer (2010) 1.18
Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer (2010) 1.14
Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer (2012) 1.14
EAU guidelines on robotic and single-site surgery in urology. Eur Urol (2013) 1.13
Bladder neck incision using a 70 W 2 micron continuous wave laser (RevoLix). World J Urol (2007) 1.11
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. Onco Targets Ther (2012) 1.08
External validation of the preoperative anatomical classification for prediction of complications related to nephron-sparing surgery. World J Urol (2010) 1.08
RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer (2007) 1.06
Thulium:YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up. World J Urol (2009) 1.04
Thulium:yttrium-aluminium-garnet laser prostatectomy in men with refractory urinary retention. BJU Int (2009) 1.03
Current evidence for transurethral laser therapy of non-muscle invasive bladder cancer. World J Urol (2011) 1.03
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep (2002) 1.02
Metastasis of malignant melanoma in the ureter: possible algorithms for a therapeutic approach. Int J Urol (2009) 1.00
The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites. Mol Microbiol (2011) 1.00
A newly designed amplatz sheath decreases intrapelvic irrigation pressure during mini-percutaneous nephrolitholapaxy: an in-vitro pressure-measurement and microscopic study. J Endourol (2007) 1.00
Thulium:YAG vapoenucleation in large volume prostates. J Urol (2011) 0.99
Laser treatment of benign prostatic obstruction: basics and physical differences. Eur Urol (2011) 0.99
Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist (2011) 0.99
High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int (2011) 0.98
Management of stones in calyceal diverticulum. Curr Opin Urol (2007) 0.97
Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study. Eur J Cancer (2012) 0.97
Urinary collecting system invasion is no independent prognostic factor in renal cell carcinoma. World J Urol (2010) 0.97
The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate (2009) 0.97
GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int (2012) 0.97
Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep (2006) 0.97
Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control (2010) 0.97
Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol Int (2008) 0.96
Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. Int J Cancer (2006) 0.95
Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers. Asian J Androl (2012) 0.95
Tissue microarrays in clinical urology--technical considerations. Scand J Urol Nephrol (2007) 0.93
Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate (2008) 0.93
The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol (2008) 0.93
Initial clinical experience with full-length metal ureteral stents for obstructive ureteral stenosis. World J Urol (2008) 0.92
The rationale for radical cystectomy as primary therapy for T4 bladder cancer. World J Urol (2007) 0.91
Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation. World J Urol (2009) 0.90
Adiposity and age are statistically related to enhanced RASSF1A tumor suppressor gene promoter methylation in normal autopsy kidney tissue. Cancer Epidemiol Biomarkers Prev (2007) 0.90
Size does matter: 1.5 Fr. stone baskets almost double irrigation flow during flexible ureteroscopy compared to 1.9 Fr. stone baskets. Urol Res (2006) 0.89
Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report. World J Urol (2012) 0.89
Laparoendoscopic single-site (LESS) varicocelectomy with reusable components: comparison with the conventional laparoscopic technique. Surg Endosc (2013) 0.89
Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy? Int J Urol (2012) 0.89
Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. Urol Oncol (2011) 0.89
Clear-cell variant urothelial carcinoma of the bladder: a case report and review of the literature. Rare Tumors (2012) 0.88
Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. Eur Urol (2012) 0.88
Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther (2012) 0.87
Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res (2005) 0.87
Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC Cancer (2013) 0.87
Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC). World J Urol (2012) 0.87
Introducing a new sealant applicator for easy, safe, and quick closure of a mini-percutaneous nephrolitholapaxy access tract. J Endourol (2007) 0.86
Nocturia: state of the art and critical analysis of current assessment and treatment strategies. World J Urol (2014) 0.86
Initial experience with laparoscopic single-incision triangulated umbilical surgery (SITUS) in simple and radical nephrectomy. World J Urol (2011) 0.85
Expression of cAMP-dependent protein kinase isoforms in the human prostate: functional significance and relation to PDE4. Urology (2010) 0.85
Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol (2008) 0.85
New ex vivo organ model for percutaneous renal surgery using a laparoendoscopic training box: the sandwich model. World J Urol (2013) 0.85
Successful Pregnancy and Neobladder Subsequent to Muscle Invasive Bladder Cancer and Fertility Preserving Surgery: Case Report and Review of the Literature. Urol Int (2015) 0.85
Tm:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer: early experience. World J Urol (2011) 0.85